Please login to the form below
Palforzia
This page shows the latest Palforzia news and features for those working in and with pharma, biotech and healthcare.
Nestlé and Seres announce new partnership for C.diff microbiome therapeutic
Aimmune’s Palforzia became the first peanut allergy drug to be cleared for use in the US last year.
Latest news
-
EU authorises Aimmune’s peanut allergy treatment Palforzia
Approval in the EU comes nine months after US authorisation. Aimmune Therapeutics’ Palforzia has received approval from the European Commission (EC) for the treatment of a peanut allergy. ... The EC has approved Palforzia for use in children aged four
-
Nestlé is set to acquire Aimmune in deal worth $2.6bn
the biopharmaceutical company’s Palforzia became the first peanut allergy drug to be cleared for use in the US. ... Aimmune’s launch of Palforzia has been hampered by the ongoing COVID-19 pandemic, as the health crisis continues to have an impact in
-
FDA knocks back DBV’s peanut allergy therapy once again
drug. Like Palforzia, the rationale for Viaskin Peanut is to expose people with peanut allergy to small amounts of antigen over time to encourage the immune system to develop tolerance. ... Every month of delay gives Aimmune more time to extend its lead
-
Aimmune’s Palforzia is first peanut allergy drug cleared in US
When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy,” added Marks. ... The company has agreed to make Palforzia
-
Aimmune gets FDA panel backing for peanut allergy therapy
The panel voted seven to two that AR101 – now given the trade name Palforzia – can reduce allergic reactions from accidental exposure to peanuts and warrants approval.
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
This year’s list also highlights three first-in class medicines compared with last year’s list, which contained only one first-in-class medicine, peanut allergy vaccine Palforzia.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Food Allergy – Is avoidance the only option?
Published January 20, 2022. Accessed April 28, 2022. PALFORZIA – Summary of Product Characteristics. ... Published July 15, 2021. Accessed April 29, 2022. Palforzia for treating peanut allergy in children and young people.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
